Skip to main content

Biomedical Research in Gynaecology

The Biomedical Research Group in Gynaecology is a multidisciplinary team made up of clinical specialists in gynaecology and pathology and basic and translational researchers. Our research is clearly translational. Although we take into account the obvious importance of understanding the mechanism at the cellular and molecular level and try to incorporate it into our research, our research is always focused on having a direct applicability to patients and their clinical benefit. On our way to transferring scientific results to clinical practice, we promote innovation and entrepreneurship.

Our group comprises four main research groups, which are closely connected: The clinical research group devoted mainly to clinical projects in all gynaecological cancers; and three translational research groups dedicated to ovarian cancer; endometrial cancer and endometriosis; diseases of the lower female genital tract.

Team

Antonio Gil Moreno

Antonio Gil Moreno

Head of group
Biomedical Research in Gynaecology
Read more
Beatriz Villafranca Magdalena

Beatriz Villafranca Magdalena

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Carina Masferrer Ferragutcasas

Carina Masferrer Ferragutcasas

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Carlos Lopez Gil

Carlos Lopez Gil

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Ma del Pilar Gutierrez Barceló

Ma del Pilar Gutierrez Barceló

Biomedical Research in Gynaecology
Read more
Ana Luzarraga Aznar

Ana Luzarraga Aznar

Senior researcher
Biomedical Research in Gynaecology
Read more
Antonio Gil Moreno

Antonio Gil Moreno

Head of group
Biomedical Research in Gynaecology
Read more
Beatriz Villafranca Magdalena

Beatriz Villafranca Magdalena

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Carina Masferrer Ferragutcasas

Carina Masferrer Ferragutcasas

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Carlos Lopez Gil

Carlos Lopez Gil

Predoctoral researcher
Biomedical Research in Gynaecology
Read more
Ma del Pilar Gutierrez Barceló

Ma del Pilar Gutierrez Barceló

Biomedical Research in Gynaecology
Read more
Ana Luzarraga Aznar

Ana Luzarraga Aznar

Senior researcher
Biomedical Research in Gynaecology
Read more

Research lines

Clinical Research in Ginecology

Research team: Dr. Antonio Gil-Moreno (Principal researcher) Dr. Assumpció Pérez-Benavente (Clinical associated investigator) Dr. José Lúís Sánchez Iglesias (Clinical associated investigator) Dra. Silvia Cabrera (Clinical associated investigator) Dr. Vicente Bebia Conesa (Clinical associated investigator) Dr. Natalia Rodríguez Gómez-Hidalgo (Clinical associated investigator) Dr. Javier de la Torre Fernández de Vega (Clinical associated investigator) Dr. José Luís Poza Barrasús (Clinical associated investigator) Dr. Sabina Salicrú Riera (Clinical associated investigator) Dr. Laura Mañalich Barrachina (Clinical associated investigator) Dr. Montse Cubo Albert (Clinical associated investigator) Dr. Cristina Centeno Mediavilla (Clinical associated investigator) Dr. Melissa Bradbury (Clinical associated investigator) Dr. Sonia Monreal (Clinical associated investigator) Dr. Angel García (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dr. Elena Suárez (Clinical associated investigator) Dr. Mireia Armengol (Clinical associated investigator/resident) Dra. Eva Colás (Translational associated researcher) Dr. Melek Denizli (Technician) Research focus. Clinical Research Lines CLINICAL ENDOMETRIAL CANCER RESEARCH - Prospective, randomized study: STELLA1-2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer. ClinicalTrials.gov Identifier: NCT01810874. - Implementation of radioguided surgery for clinically occult lesions (ROLL) in abdominal recurrences of gynecological tumors. - MULTISENT study: Ambiespective multicenter study of sentinel node biopsy in initial endometrial cancer. - Concordance study between morphological techniques and OSNA (one-step nucleic cid amplification) for the detection of lymph node metastases in endometrial carcinoma. - Preoperative staging of endometrial carcinoma by ultrasound 2D and 3D. CLINICAL OVARIAN CANCER RESEARCH - Prospective study: Postoperatory Recovery in Advanced Ovarian Cancer, Fast-Track Protocol vs. Classical Management (PROFAST). ClinicalTrials.gov Identifier: NCT02172638. - EDMOCS study in ovarian cancer. - SIMACEO study: Current Situation of the Management of Epithelial Cancer of the Ovary in initial stages in Spain. CLINICAL CERVICAL CANCER RESEARCH - Prospective study of validation of sentinel lymph node detection technique in early cervical cancer (FIGO 2018 stages IA2-IB1-IB2-IIA1). - Collaborating center in the RACC Trial study (PI: Karolynska Hospital, Sweden): International, Prospective, Randomized comparative study of robotic versus laparotomic radical hysterectomy approach in early cervical cancer. - Validation of robotic assisted and laparoscopic aortic extraperitoneal lymphadenectomy in recurrences of gynaecologic malignancies. - Preoperative staging of carcinoma of the uterine cervix by ultrasound 2D and 3D. CLINICAL RESEARCH IN BENIGN GYNECOLOGY - Prospective study: Multicentric Comparative Randomized Study of the Single-incision Sling Ajust® Versus Suburethral Transobturator Slings. ClinicalTrials.gov Identifier: NCT01699425 - “A 3 Years Naturalistic Cohort Survey Of Altis® Single Incision Sling System For Female Stress Urinary Incontinence. A post-marketing and multicenter prospective observational cohort study in subjects with female stress urinary incontinence”. - "Non-interventional study to evaluate quality of life, satisfaction with treatment, use of resources and persistence in treatment in patients with overactive bladder (OAB) who were prescribed Betmiga". - “Comparative study of polyvinylidene fluoride and polypropylene suburethral-slings in the treatment of female stress urinary incontinence.” - “Microarray analysis of differentially expressed genes in samples from patients with pelvic organ prolapse.” Estudio EME: “Estudio epidemiológico sobre la miomatosis uterina en España”. CLINICAL RESEARCH: MISCELLANEOUS Prospective study of validation of sentinel lymph node detection technique in early vulvar cancer (early stages FIGO 2009) - Prospective study of quality of life in patients with BRCA1-2 after risk-reducing adnexectomy. - Prospective study of quality of life in patients with BRCA1-2 after risk-reducing mastectomy. - Early detection of preneoplastic tubal lesions to delay ovarian cancer risk-reducing surgery in patients with BRCA1/2 mutations. - Prospective, multicenter study for the evaluation of the intraoperative HPV test. - INCIP Study: Cancer in pregnancy - Randomized, open, multicentric, parallel group and control group clinical trial to evaluate the effect of PAPILOCARE® in the normalization of cytological alterations of the cervix caused by HPV (PALOMA II Clinical Trial). - Cervical epithelium methylation as a risk marker of progression to HSIL in women with normal cytology and positive HPV. - Conservative management of high-risk cervical intraepithelial lesions. - Utility of DySIS® in the diagnosis and management of intraepithelial lesions of the lower genital tract. - Breast Cancer During Pregnancy (BRCAPRE). ClinicalTrials.gov Identifier: NCT02102282.

IP: Antonio Gil Moreno

Endometrial Cancer and Endometriosis Research

Research team: Dr. Eva Colas (Principal researcher) Dr. Cristian Moiola (Post-doctoral researcher) Dr. Eva Coll (PhD student) Dr. Carlos López (PhD student) Dr. Carina Masferrer (PhD student) Dr. Beatriz Villafranca (PhD student) Dr. Melek Denizli (Technician) Dr. Marta Rebull (Technician) Dr. Aida Soler (Technician) Dr. Antonio Gil-Moreno (Principal researcher) Dra. Silvia Cabrera (Clinical associated investigator) Dr. Angel García (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dra. Elena Suárez (Clinical associated investigator) Dra. Mireia Armengol (Clinical associated investigator/resident) Research focus IMPLEMENTATION OF MOLECULAR DIAGNOSTICS IN ENDOMETRIAL CANCER Early detection is directly related to an increased survival for endometrial cancer patients. Diagnosis of endometrial cancer initiates with the presence of symptoms, i.e. an abnormal vaginal bleeding, and 1 of every 10 women with this symptom will have an endometrial cancer. In order to improve early detection, we aim to improve the process of diagnosis by implementing molecular markers in proximal bodily fluids. Thus, we expect to minimize invasiveness whilst increase accuracy on the newly developed methods of diagnosis. In this research line, the group has two ongoing projects: Proteomic biomarkers for an improved diagnosis in uterine aspirates. Exploitation of pap-smears as an untapped source of biomarkers of endometrial cancer. PREVENTING DISTANT AND LOCAL DISSEMINATION OF ENDOMETRIAL CANCER CELLS Once a patient is diagnosed, the presence of prognostic factors are used to classify patients according to their risk of recurrence, which directly affects their clinical management. However, up to 20% of patients diagnosed at early stages, and up to 50% of patients diagnosed in advanced stages will suffer a relapse without means of predicting it. We aim to understand the mechanisms of local and distant tumour dissemination to develop strategies that prevent tumour relapse. Moreover, we aim to design tools to better estimate the risk of recurrence of endometrial cancer patients. In this research line, the group has two ongoing projects: Understanding the molecular mechanisms associated to local and distant dissemination via studying the MELF component and the exosomes derived from the tumor. Deciphering biomarkers of recurrence in endometrial cancer. DEVELOPING INDIVIDUALIZED TREATMENT FOR ENDOMETRIAL CANCER PATIENTS Nowadays, adjuvant treatment of metastatic or recurrent endometrial cancer patients is restricted to few therapeutic options, mostly based on radiotherapy and conventional chemotherapy regimens. Advances in understanding the molecular landscape of endometrial cancer have arisen the development of targeted therapies. However, responses to these targeted therapies are modest, probably due to the underestimation of the heterogeneity found in cancer, misrepresentation of low frequent subtypes of cancer, as well as the lack of clinically relevant models to perform pre-clinical studies, among other issues. The group aims to develop clinically relevant models and design experimental treatments in order to increase the response rate of patients. In this research line, the group has 2 ongoing projects: The U-CAN platform of endometrial cancer PDX models to perform preclinical studies. Identification of new experimental therapies. Real-time oncology. MOLECULAR DIAGNOSIS AND RECURRENCE PREDICTION IN ENDOMETRIOSIS Endometriosis is an estrogen dependent disease that affects approximately 15% of women in reproductive age. Although endometriosis is considered a benign disease, characterized by the presence of uterine tissue outside the uterus, it causes strong pain and, often, infertility. So far, the gold standard method to diagnose endometriosis is laparoscopy, an invasive technique and there are no methods for early diagnose of the disease. In addition, patients undergoing surgery as a definitive treatment of endometriosis might recur without means of predicting it. In this research line, the group has 2 ongoing projects: Assess the potential of angiogenic factors to diagnose and predict recurrence in endometriosis. Identification of biomarkers to predict recurrence in endometrioma using a proteomic and transcriptomic approach.

IP: Eva Colas Ortega

Ovarian Cancer Research

Research team: Dr. Melissa Bardbury (Principal researcher) Dr. Antonio Gil-Moreno (Principal researcher) Dra. Anna Santamaría (Stable collaborator) Dr. Eva Coll (PhD student) Dr. Carlos López (PhD student) Dr. Melek Denizli (Technician) Dr. José Luís Sánchez Iglesias (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dr. Assumpció Pérez-Benavente (Clinical associated investigator) Dr. Vicente Bebia Conesa (Clinical associated investigator) Dr. Natalia Rodríguez Gómez-Hidalgo (Clinical associated investigator) Dr. Javier de la Torre Fernández de Vega (Clinical associated investigator) Research focus PERIOPERATIVE IMMUNOMODULATION IN OVARIAN CANCER Surgery for advanced ovarian cancer is a stressful stimulus that results in a pro-catabolic hormonal and cytokine environment, which significantly impacts metabolism. This metabolic response is accompanied by immune system impairment, increasing the risk of post-operative complications. In this research line the group is working in a multidisplinary project within the ERAS® program at the Vall d’Hebron Hospital for the: Identification of inflammatory markers predicting improved recovery after surgery within an ERAS® protocol. MOLECULAR DIAGNOSTICS AND PREDICTION OF TREATMENT RESPONSE IN OVARIAN CANCER Ovarian cancer remains the leading cause of death from gynecological malignancies due to its late diagnosis and high recurrence rates following treatment. There is a need to improve the early detection of the disease and identify predictive markers of treatment response. These diagnostic and predictive markers are being identified in proximal body fluids and patient-tissue samples. In this research line, the group has 3 ongoing projects: Proteomic biomarkers for an improved diagnosis in uterine aspirates and pap-smears. Proteomic biomarkers for the prediction of treatment response. SalivOmiX: A salivary miRNA-based test for ovarian cancer early diagnosis.

IP: Melissa Bradbury Lobato, Antonio Gil Moreno

Preinvasive and invasive disease of the lower genital tract research

Research team: Dr. Melissa Bradbury (Principal researcher) Dr. Cristina Centeno (Clinical associated investigator) Dr. Antonio Gil-Moreno (Principal researcher) Dr. Carme Dinarés (Clinical associated investigator) Dr. Josep Castellví (Clinical associated investigator) Dr. Armando Reques (Clinical associated investigator) Dr. Angel Garcia (Clinical associated investigator) Dra. Eva Colás (Translational associated researcher) Dr. Melek Denizli (Technician) Research focus NEW MARKERS FOR THE DIAGNOSIS AND PROGRESSION OF INTRAEPITHELIAL NEOPLASIA OF THE LOWER GENITAL TRACT Persistent infections with high-risk human papillomavirus (HPV) genotypes are necessary, but not sufficient, cause of preinvasive and invasive lesions of the cervix and the lower genital tract. Although cancer screening prevention is based on HPV screening and pap-smear tests, it is essential to identify new molecular markers that can predict the transformation of HPV-associated lesions. In this research line our group is assessing: Identification of molecular markers associated to an increased risk of development, persistence and progression of preinvasive lesions of the lower genital tract.

IP: Melissa Bradbury Lobato

Projects

Metilación en epitelio cervical como marcador de riesgo de progresión a HSIL en mujeres citología normal y VPH positivo.

IP: Úrsula Acosta Sánchez
Collaborators: -
Funding agency: Asoc.Esp.Pat.Cervical y Colposcopia AEPCC
Funding: 1200
Reference: AEPCC/PREMI.INVEST/2019/ACOSTA
Duration: 31/12/2020 - 30/12/2022

-

IP: Silvia Cabrera Diaz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: PI17/02155_INT_CABRERA
Duration: 01/02/2019 - 30/06/2022

Nuevas estrategias para incrementar la eficacia de los tratamientos de ABTL0812 en cáncer de endometrio.

IP: Antonio Gil Moreno
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: IFI19/00029
Duration: 01/01/2020 - 28/02/2022

Nuevos métodos para el control de la recurrencia en cáncer de endometrio

IP: Antonio Gil Moreno
Collaborators: Eva Colas Ortega, Miriam Izquierdo Sans
Funding agency: Asociación Española Contra el Cáncer
Funding: 100000
Reference: AECC/PERSONALINV/2020/COLAS
Duration: 29/09/2020 - 28/09/2022

Metilación en epitelio cervical como marcador de riesgo de progresión a HSIL en mujeres citología normal y VPH positivo.

IP: Úrsula Acosta Sánchez
Collaborators: -
Funding agency: Asoc.Esp.Pat.Cervical y Colposcopia AEPCC
Funding: 1200
Reference: AEPCC/PREMI.INVEST/2019/ACOSTA
Duration: 31/12/2020 - 30/12/2022

Aproximació a la medicina personalitzada en càncer d'endometri pel control de la malaltia recidivant

IP: Antonio Gil Moreno
Collaborators: Carlos Lopez Gil, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 46200
Reference: 2018 FI_B 00573
Duration: 01/03/2018 - 07/06/2021

-

IP: Silvia Cabrera Diaz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: PI17/02155_INT_CABRERA
Duration: 01/02/2019 - 30/06/2022

Nuevas estrategias para incrementar la eficacia de los tratamientos de ABTL0812 en cáncer de endometrio.

IP: Antonio Gil Moreno
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 82400
Reference: IFI19/00029
Duration: 01/01/2020 - 28/02/2022

Metilación en epitelio cervical como marcador de riesgo de progresión a HSIL en mujeres citología normal y VPH positivo.

IP: Úrsula Acosta Sánchez
Collaborators: -
Funding agency: Asoc.Esp.Pat.Cervical y Colposcopia AEPCC
Funding: 1200
Reference: AEPCC/PREMI.INVEST/2019/ACOSTA
Duration: 31/12/2020 - 30/12/2022

Desenvolupament d'una eina de diagnòstic no invasiva en el càncer d'endometri

IP: Antonio Gil Moreno
Collaborators: Eva Colas Ortega, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 104111.51
Reference: SLT002/16/00315
Duration: 01/04/2017 - 28/09/2020

Aproximació a la medicina personalitzada en càncer d'endometri pel control de la malaltia recidivant

IP: Antonio Gil Moreno
Collaborators: Carlos Lopez Gil, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 46200
Reference: 2018 FI_B 00573
Duration: 01/03/2018 - 07/06/2021

-

IP: Silvia Cabrera Diaz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: PI17/02155_INT_CABRERA
Duration: 01/02/2019 - 30/06/2022

Desenvolupament d'una eina de diagnòstic no invasiva en el càncer d'endometri

IP: Antonio Gil Moreno
Collaborators: Eva Colas Ortega, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 104111.51
Reference: SLT002/16/00315
Duration: 01/04/2017 - 28/09/2020

Aproximació a la medicina personalitzada en càncer d'endometri pel control de la malaltia recidivant

IP: Antonio Gil Moreno
Collaborators: Carlos Lopez Gil, Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 46200
Reference: 2018 FI_B 00573
Duration: 01/03/2018 - 07/06/2021

-

IP: Silvia Cabrera Diaz
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: PI17/02155_INT_CABRERA
Duration: 01/02/2019 - 30/06/2022

Patrón de infiltración MELF en carcinoma endometrioide: estudio de las características clínico-patológicas y moleculares

IP: Eva Colas Ortega
Collaborators: Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 35000
Reference: HUVH/BPFSE/2019/REQUES
Duration: 01/06/2019 - 23/01/2020

Titol projecte associat: Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment.

IP: Antonio Gil Moreno
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 48600
Reference: 2015 FI_B 00703
Duration: 01/03/2015 - 28/02/2018

Projecte: Understanding the role of LGR5 in endometriosis. Empresa: IVI Barcelona, S.L.

IP: Xavier Santamaria Costa
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 27360
Reference: 2015 DI 074
Duration: 01/01/2016 - 31/12/2018

Unraveling the mechanisms responsible for metastasis formation and identification of new therapeutical approaches in endometrial cancer

IP: Antonio Gil Moreno
Collaborators: Cristian Pablo Moiola , Miriam Izquierdo Sans
Funding agency: EUROPEAN COMMISSION
Funding: 42720
Reference: INCOMED - FELLOW 3
Duration: 01/03/2016 - 28/02/2018

Desenvolupament d'una eina de diagnòstic no invasiva en el càncer d'endometri

IP: Antonio Gil Moreno
Collaborators: Eva Colas Ortega, Miriam Izquierdo Sans
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 104111.51
Reference: SLT002/16/00315
Duration: 01/04/2017 - 28/09/2020

Protein signatures improve diagnosis "The CEMARK project"

IP: -
Collaborators: -
Funding agency: CERCA (Centres de Recerca de Catalunya)
Funding: 1000
Reference: CERCA/PIONER/2017/ELENA MARTINEZ
Duration: 15/12/2017 - 15/12/2017

Titol projecte associat: Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment.

IP: Antonio Gil Moreno
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 48600
Reference: 2015 FI_B 00703
Duration: 01/03/2015 - 28/02/2018

Unraveling the mechanisms responsible for metastasis formation and identification of new therapeutical approaches in endometrial cancer

IP: Antonio Gil Moreno
Collaborators: Cristian Pablo Moiola , Miriam Izquierdo Sans
Funding agency: EUROPEAN COMMISSION
Funding: 42720
Reference: INCOMED - FELLOW 3
Duration: 01/03/2016 - 28/02/2018

Projecte: Understanding the role of LGR5 in endometriosis. Empresa: IVI Barcelona, S.L.

IP: Xavier Santamaria Costa
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 27360
Reference: 2015 DI 074
Duration: 01/01/2016 - 31/12/2018

Identificación de nuevas moléculas y mecanismos de infiltración miometrial y diagnóstico precoz para incrementar la supervivencia del cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 52258
Reference: FPU12/05571
Duration: 01/04/2013 - 31/08/2016

Identificación de marcadors proteòmics en biofluids de pacients amb càncer d'ovari per la millora del seu diagnòstic i pronòstic

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 18146.88
Reference: FI-DGR-2013-10
Duration: 01/01/2013 - 01/01/2016

Titol projecte associat: Genomic approach for individualizing endometrial cancer diagnosis, prognosis and treatment.

IP: Antonio Gil Moreno
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 48600
Reference: 2015 FI_B 00703
Duration: 01/03/2015 - 28/02/2018

Unraveling the mechanisms responsible for metastasis formation and identification of new therapeutical approaches in endometrial cancer

IP: Antonio Gil Moreno
Collaborators: Cristian Pablo Moiola , Miriam Izquierdo Sans
Funding agency: EUROPEAN COMMISSION
Funding: 42720
Reference: INCOMED - FELLOW 3
Duration: 01/03/2016 - 28/02/2018

Perfils d'expressió de miRNAs com a predictors de risc i l'agressivitat del càncer de pròstata

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 39930
Reference: FI-DGR-2012-07
Duration: 01/03/2012 - 28/02/2015

Identificación de nuevas moléculas y mecanismos de infiltración miometrial y diagnóstico precoz para incrementar la supervivencia del cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 52258
Reference: FPU12/05571
Duration: 01/04/2013 - 31/08/2016

Unitat de recerca biomèdica i oncologia translacional i pediàtrica

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 108000
Reference: CD12/00475
Duration: 01/01/2013 - 31/12/2015

Identificación de marcadors proteòmics en biofluids de pacients amb càncer d'ovari per la millora del seu diagnòstic i pronòstic

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 18146.88
Reference: FI-DGR-2013-10
Duration: 01/01/2013 - 01/01/2016

Perfils d'expressió de miRNAs com a predictors de risc i l'agressivitat del càncer de pròstata

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 39930
Reference: FI-DGR-2012-07
Duration: 01/03/2012 - 28/02/2015

Identificación de nuevas moléculas y mecanismos de infiltración miometrial y diagnóstico precoz para incrementar la supervivencia del cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 52258
Reference: FPU12/05571
Duration: 01/04/2013 - 31/08/2016

Unitat de recerca biomèdica i oncologia translacional i pediàtrica

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 108000
Reference: CD12/00475
Duration: 01/01/2013 - 31/12/2015

Identificación de marcadors proteòmics en biofluids de pacients amb càncer d'ovari per la millora del seu diagnòstic i pronòstic

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 18146.88
Reference: FI-DGR-2013-10
Duration: 01/01/2013 - 01/01/2016

Perfils d'expressió de miRNAs com a predictors de risc i l'agressivitat del càncer de pròstata

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 39930
Reference: FI-DGR-2012-07
Duration: 01/03/2012 - 28/02/2015

Identificación de nuevas moléculas y mecanismos de infiltración miometrial y diagnóstico precoz para incrementar la supervivencia del cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Ministerio de Educación, Cultura y Deporte
Funding: 52258
Reference: FPU12/05571
Duration: 01/04/2013 - 31/08/2016

Unitat de recerca biomèdica i oncologia translacional i pediàtrica

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 108000
Reference: CD12/00475
Duration: 01/01/2013 - 31/12/2015

Identificación de marcadors proteòmics en biofluids de pacients amb càncer d'ovari per la millora del seu diagnòstic i pronòstic

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 18146.88
Reference: FI-DGR-2013-10
Duration: 01/01/2013 - 01/01/2016

Ayuda para la preparación de la propuesta del proyecto "Validating new therapies for ovarian cancer" (THEROVCA)

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 3000
Reference: SAF2011-13212-E
Duration: 01/01/2012 - 31/12/2012

Ministerio de Ciencia

Caracterización melecular de los procesos de infiltración y diseminación tumorales y desarrollo de metástasis en cáncer de endometrio. Papel de RUNX1 en la promoción de las metástasis.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13500
Reference: PRED/IR-HUVH/12/2008
Duration: 01/01/2009 - 31/12/2012

Perfils d'expressió de miRNAs com a predictors de risc i l'agressivitat del càncer de pròstata

IP: Jaume Reventós Puigjaner
Collaborators: Miriam Izquierdo Sans
Funding agency: AGAUR
Funding: 39930
Reference: FI-DGR-2012-07
Duration: 01/03/2012 - 28/02/2015

Proteomic identification of biomarkers and biofluids and in preclinical models for the early diagnosis and prognosis of cancer (PROTBIOFLUID) Grant Agreement nº 269285

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: EUROPEAN COMMISSION
Funding: 157500
Reference: PROTBIOFLUID_FP7IRSES2010
Duration: 01/08/2011 - 31/07/2015

Ajut per a la preparació de la proposta del projecte "Proteomic Identification of Biomarkers and Biofluids and in Preclinical Models for the Early Diagnosis of Cancer - PROTBIOFLUID"

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 5000
Reference: SAF2010-10635-E
Duration: 16/12/2010 - 15/12/2011

Ministerio de Ciencia

Análisis de la expresión génica diferencial en diferentes estadíos del sesarrollo del cáncer de ovario

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00423
Duration: 01/01/2008 - 31/12/2011

Caracterización melecular de los procesos de infiltración y diseminación tumorales y desarrollo de metástasis en cáncer de endometrio. Papel de RUNX1 en la promoción de las metástasis.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding: 13500
Reference: PRED/IR-HUVH/12/2008
Duration: 01/01/2009 - 31/12/2012

Caracterización Molecular de los procesos de infiltración y diseminación tumorales y desarrollo de metástasis en cáncer de endometrio. Papel de RUNX1 en la promoción de las metástasis.

IP: Jaume Reventós Puigjaner
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 96800
Reference: SAF2008-03996
Duration: 01/01/2009 - 31/12/2011

Ministerio de Ciencia

Ajut per a la preparació de la proposta del projecte "Proteomic Identification of Biomarkers and Biofluids and in Preclinical Models for the Early Diagnosis of Cancer - PROTBIOFLUID"

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 5000
Reference: SAF2010-10635-E
Duration: 16/12/2010 - 15/12/2011

Ministerio de Ciencia

Caracterización de RUNX1/AML1 y ERM/ETV5 durante los procesos de infltración miometrial y metástasis en cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30431.7
Reference: MS05/00240
Duration: 01/02/2006 - 31/01/2010

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

Análisis de la expresión génica diferencial en diferentes estadíos del sesarrollo del cáncer de ovario

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 54000
Reference: FI07/00423
Duration: 01/01/2008 - 31/12/2011

Caracterización de RUNX1/AML1 y ERM/ETV5 durante los procesos de infltración miometrial y metástasis en cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30431.7
Reference: MS05/00240
Duration: 01/02/2006 - 31/01/2010

Detección de los marcadores precoces (RUNX/AML1 y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: POST/IR-HUVH/12/2005
Duration: 01/05/2006 - 28/02/2009

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

Detecció de marcadors precoços (RUNX1/AML1 i ERM/ETV5 ) d'invasió miometrial i metastatització en el carcinoma d'endometri: caracterització dels seus mecanismes d'acció

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: AGAUR
Funding: 63800
Reference: 2006 BP B1 00160
Duration: 01/01/2008 - 31/12/2009

Detección de los marcadores precoces (RUNX/AML1 y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: POST/IR-HUVH/12/2005
Duration: 01/05/2006 - 28/02/2009

Caracterización de RUNX1/AML1 y ERM/ETV5 durante los procesos de infltración miometrial y metástasis en cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30431.7
Reference: MS05/00240
Duration: 01/02/2006 - 31/01/2010

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

Detecció de marcadors precoços (RUNX1/AML1 i ERM/ETV5 ) d'invasió miometrial i metastatització en el carcinoma d'endometri: caracterització dels seus mecanismes d'acció

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: AGAUR
Funding: 63800
Reference: 2006 BP B1 00160
Duration: 01/01/2008 - 31/12/2009

Detección de los marcadores precoces (RUNX/AML1 y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: POST/IR-HUVH/12/2005
Duration: 01/05/2006 - 28/02/2009

Caracterización de RUNX1/AML1 y ERM/ETV5 durante los procesos de infltración miometrial y metástasis en cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30431.7
Reference: MS05/00240
Duration: 01/02/2006 - 31/01/2010

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

Projecte ONCNOSIS

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: AGAUR
Funding: 47850
Reference: 2006 BP B2 00017
Duration: 01/05/2007 - 30/04/2009

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un panel de 297 secuencias diferencialmente expresadas halladas por hibridación de microarrays

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9366
Duration: 15/10/2002 - 27/12/2006

Detección de los marcadores precoces (RUNX/AML1 y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Fundació Institut de Recerca HUVH
Funding:
Reference: POST/IR-HUVH/12/2005
Duration: 01/05/2006 - 28/02/2009

Caracterización de RUNX1/AML1 y ERM/ETV5 durante los procesos de infltración miometrial y metástasis en cáncer de endometrio

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 30431.7
Reference: MS05/00240
Duration: 01/02/2006 - 31/01/2010

Detección de los marcadores precoces ((RUNX/AML1 Y ERM/ETV5) de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Eva Colas Ortega
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 53000
Reference: BES-2006-14152
Duration: 01/09/2006 - 31/08/2010

Ministerio de Ciencia

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un panel de 297 secuencias diferencialmente expresadas halladas por hibridación de microarrays

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9366
Duration: 15/10/2002 - 27/12/2006

Análisis cinético de la expresión génica y de la adoptosis de los distintos tipos celulares prostáticos durante el desarrollo y la regresión de la hiperplasia benigna de próstata en el perro

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia y Tecnología
Funding: 69000
Reference: SAF2002-00980
Duration: 01/11/2002 - 01/11/2005

Detección de los marcadores precoces RUNX/AML1 y ERM/ETV5 de invasión miometrial y metastatización en el carcinoma de endometrio: caracterización de los mecanismos de acción

IP: Jaume Reventós Puigjaner
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 142800
Reference: SAF2005-06771
Duration: 15/10/2005 - 14/10/2008

Ministerio de Ciencia

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un papel de 297 secuencias diferencialmente expresadas halladas por hibridación de Microarrays.

IP: Angel García Jiménez
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 65435
Reference: PI020733
Duration: 06/11/2002 - 30/06/2006

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un panel de 297 secuencias diferencialmente expresadas halladas por hibridación de microarrays

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9366
Duration: 15/10/2002 - 27/12/2006

Análisis cinético de la expresión génica y de la adoptosis de los distintos tipos celulares prostáticos durante el desarrollo y la regresión de la hiperplasia benigna de próstata en el perro

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia y Tecnología
Funding: 69000
Reference: SAF2002-00980
Duration: 01/11/2002 - 01/11/2005

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un papel de 297 secuencias diferencialmente expresadas halladas por hibridación de Microarrays.

IP: Angel García Jiménez
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 65435
Reference: PI020733
Duration: 06/11/2002 - 30/06/2006

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un panel de 297 secuencias diferencialmente expresadas halladas por hibridación de microarrays

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9366
Duration: 15/10/2002 - 27/12/2006

Análisis cinético de la expresión génica y de la adoptosis de los distintos tipos celulares prostáticos durante el desarrollo y la regresión de la hiperplasia benigna de próstata en el perro

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia y Tecnología
Funding: 69000
Reference: SAF2002-00980
Duration: 01/11/2002 - 01/11/2005

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un papel de 297 secuencias diferencialmente expresadas halladas por hibridación de Microarrays.

IP: Angel García Jiménez
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 65435
Reference: PI020733
Duration: 06/11/2002 - 30/06/2006

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un panel de 297 secuencias diferencialmente expresadas halladas por hibridación de microarrays

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding:
Reference: BEFI 02/9366
Duration: 15/10/2002 - 27/12/2006

Revisión de la valoración de la amplificación génica del c-erbB2 en el diagnóstico y pronóstico del cancer de endometrio. Establecimiento de un proceso metodológico diagnóstico de análisis de la amplificación génica por la técnica de PCR en tiempo real e

IP: Jaume Reventós Puigjaner
Collaborators: Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 7500
Reference: AETS_01/10076
Duration: 01/01/2002 - 31/12/2002

Análisis cinético de la expresión génica y de la adoptosis de los distintos tipos celulares prostáticos durante el desarrollo y la regresión de la hiperplasia benigna de próstata en el perro

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Ministerio de Ciencia y Tecnología
Funding: 69000
Reference: SAF2002-00980
Duration: 01/11/2002 - 01/11/2005

Identificación de marcadores tumorales del adenocarcinoma endometrial a partir de un papel de 297 secuencias diferencialmente expresadas halladas por hibridación de Microarrays.

IP: Angel García Jiménez
Collaborators: Josep Castellví Vives, Antonio Gil Moreno
Funding agency: Instituto de Salud Carlos III
Funding: 65435
Reference: PI020733
Duration: 06/11/2002 - 30/06/2006

Identificación de factores implicados en la proliferación celular y la progresión tumoral en el cáncer de endometrio.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 63707.28
Reference: 99/0897
Duration: 01/11/1999 - 01/11/2000

Bases moleculares de la enfermedad prostática: identificación de marcadores de diagnóstico precoz, de evolución y de pronóstico.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 42972.37
Reference: 98/0199
Duration: 01/11/1998 - 01/11/1999

Identificación de factores implicados en la proliferación celular y la progresión tumoral en el cáncer de endometrio.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 63707.28
Reference: 99/0897
Duration: 01/11/1999 - 01/11/2000

Bases moleculares de la enfermedad prostática: identificación de marcadores de diagnóstico precoz, de evolución y de pronóstico.

IP: Jaume Reventós Puigjaner
Collaborators: -
Funding agency: Instituto de Salud Carlos III
Funding: 42972.37
Reference: 98/0199
Duration: 01/11/1998 - 01/11/1999

Publications

Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.

PMID: 34138797
Journal: AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Year: 2022
Reference: Am J Surg Pathol. 2022 Jan 1;46(1):105-117. doi: 10.1097/PAS.0000000000001756.
Impact factor: 6.394
Publication type: Paper in international publication
Authors: Collins, Katrina; Ramalingam, Preetha; Euscher, Elizabeth D; Reques Llanos, Armando; Garcia, Angel; Malpica, Anais et al.
DOI: 10.1097/PAS.0000000000001756

Can We Reduce Overtreatment of Cervical High-Grade Squamous Intraepithelial Lesions?

PMID: 34928250
Journal: Journal of Lower Genital Tract Disease
Year: 2022
Reference: J Low Genit Tract Dis. 2022 Jan 1;26(1):20-26. doi: 10.1097/LGT.0000000000000635.
Impact factor: 1.925
Publication type: Paper in international publication
Authors: Bradbury, Melissa; Dinares, Maria Carme; Sainz, Alex; Castellet, Cristina; Perez-Benavente, Assumpcio; Gil-Moreno, Antonio; Centeno, Cristina; Murcia, Maria Teresa; Rabasa, Jordi et al.
DOI: 10.1097/LGT.0000000000000635

Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-independent Tumor Associated With Poor Outcome: A Comprehensive Analysis of 58 Cases.

PMID: 34985047
Journal: AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Year: 2022
Reference: Am J Surg Pathol. 2022 Jun 1;46(6):765-773. doi: 10.1097/PAS.0000000000001863. Epub 2022 Jan 5.
Impact factor: 6.394
Publication type: Paper in international publication
Authors: Park, Kay J; Stolnicu, Simona; Karpathiou, Georgia; Guerra, Esther; Mateoiu, Claudia; Reques, Armando; Bart, Joost; Felix, Ana; Fani, Daniela; Gama, Joao et al.
DOI: 10.1097/PAS.0000000000001863

Long-term outcomes of transobturator suburethral tapes for female stress urinary incontinence.

PMID: 34783388
Journal: NEUROUROLOGY AND URODYNAMICS
Year: 2022
Reference: Neurourol Urodyn. 2022 Jan;41(1):391-398. doi: 10.1002/nau.24835. Epub 2021 Nov 16.
Impact factor: 2.696
Publication type: Paper in international publication
Authors: Sabadell, Jordi; Montero-Armengol, Anabel; Salicru, Sabina; Catalan-Martinez, Marina; Gil-Moreno, Antonio; Poza, Jose L et al.
DOI: 10.1002/nau.24835

Value of Preoperative Use of Statins as a Protective Factor for Severe Graft Dysfunction After Lung Transplantation: A Multicenter Propensity Score Analysis.

PMID: 35699020
Journal: ARCHIVOS DE BRONCONEUMOLOGIA
Year: 2021
Reference: Arch Bronconeumol. 2021 Nov;57(11):720-722. doi: 10.1016/j.arbr.2021.04.015.
Impact factor: 4.872
Publication type: Letter or abstract
Authors: Jauregui, Alberto, Pont, Teresa, Deu, Maria, Sacanell, Judith, Gomez, Aroa, Ussetti, Piedad, Crowley, Silvana, Minambres, Eduardo, Mora, Victor, Alvarez, Carlos et al.
DOI: 10.1016/j.arbr.2021.04.015

Retro cervical tunneling to ensure correct placement for robotic-assisted transabdominal cerclage.

PMID: 34579826
Journal: FERTILITY AND STERILITY
Year: 2021
Reference: Fertil Steril. 2021 Oct;116(4):1195-1196. doi: 10.1016/j.fertnstert.2021.08.021.
Impact factor: 7.329
Publication type: Paper in international publication
Authors: Suarez-Salvador, Elena, Goya, Maria, Acosta, Ursula, Vargas, Mireia, Bradbury, Melissa, Carreras, Elena, Gil-Moreno, Antonio et al.
DOI: 10.1016/j.fertnstert.2021.08.021

Recurrent superinfection in a patient with transjugular intrahepatic portosystemic shunt (endotipsitis), findings on (18)F-FDG PET/CT.

PMID: 34425974
Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular
Year: 2021
Reference: Rev Esp Med Nucl Imagen Mol (Engl Ed). 2021 Sep-Oct;40(5):320-321. doi: 10.1016/j.remnie.2021.03.001. Epub 2021 Mar 11.
Impact factor: 1.359
Publication type: Letter or abstract
Authors: Villasboas-Rosciolesi, D, Simo-Perdigo, M, Castell-Conesa, J, Aguade-Bruix, S et al.
DOI: 10.1016/j.remnie.2021.03.001

Importance of Enhanced Recovery After Surgery (ERAS) Protocol Compliance for Length of Stay in Ovarian Cancer Surgery.

PMID: 34091804
Journal: ANNALS OF SURGICAL ONCOLOGY
Year: 2021
Reference: Ann Surg Oncol. 2021 Dec;28(13):8979-8986. doi: 10.1245/s10434-021-10228-2. Epub 2021 Jun 6.
Impact factor: 5.344
Publication type: Paper in international publication
Authors: Gil-Moreno, Antonio, Nelson, Gregg, Bradbury, Melissa, Gutierrez-Barcelo, Pilar, Serrano, Monica Pamies, Sanchez-Iglesias, Jose Luis, Gomez-Hidalgo, Natalia R, Perez-Benavente, Asuncion, Carbonell-Socias, Melchor, Manrique-Munoz, Susana et al.
DOI: 10.1245/s10434-021-10228-2

Preoperative risk stratification in endometrial cancer (ENDORISK) by a Bayesian network model: A development and validation study.

PMID: 32413043
Journal: PLOS MEDICINE
Year: 2020
Reference: PLoS Med. 2020 May 15;17(5):e1003111. doi: 10.1371/journal.pmed.1003111. eCollection 2020 May.
Impact factor: 10.5
Publication type: Paper in international publication
Authors: Reijnen, Casper, Gogou, Evangelia, Visser, Nicole C M, Engerud, Hilde, Pijnenborg, Johanna M A, Lucas, Peter J F, Kusters-Vandevelde, Heidi V N, Snijders, Marc P L M, Massuger, Leon F A G, Ramjith, Jordache et al.
DOI: 10.1371/journal.pmed.1003111

Prognostic Biomarkers in Endometrial Cancer: A Systematic Review and Meta-Analysis.

PMID: 32560580
Journal: Journal of Clinical Medicine
Year: 2020
Reference: J Clin Med. 2020 Jun 17;9(6). pii: jcm9061900. doi: 10.3390/jcm9061900.
Impact factor: 3.303
Publication type: Review in international publication
Authors: Gil-Moreno, Antonio, Cabrera, Silvia, Colas, Eva, Dittmar, Gunnar, Martinez-Garcia, Elena, Coll-de la Rubia, Eva et al.
DOI: 10.3390/jcm9061900

Potential strategies for prevention of tumor spillage in minimally invasive radical hysterectomy.

PMID: 32808499
Journal: Journal of Gynecologic Oncology
Year: 2020
Reference: J Gynecol Oncol. 2020 Sep;31(5):e73. doi: 10.3802/jgo.2020.31.e73.
Impact factor: 3.304
Publication type: Paper in international publication
Authors: Bebia, Vicente, Monreal-Clua, Sonia, Perez-Benavente, Assumpcio, Franco-Camps, Silvia, Diaz-Feijoo, Berta, Gil-Moreno, Antonio et al.
DOI: 10.3802/jgo.2020.31.e73

Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.

PMID: 32705231
Journal: ONCOLOGY REPORTS
Year: 2020
Reference: Oncol Rep. 2020 Sep;44(3):873-886. doi: 10.3892/or.2020.7648. Epub 2020 Jun 16.
Impact factor: 3.417
Publication type: Paper in international publication
Authors: Argibay, Maria Cecilia, Abba, Martin, Furlong, Laura Ines, Colas, Eva, Gil-Moreno, Antonio, Reventos, Jaume, Bello, Ricardo, Vazquez-Levin, Monica Hebe, Lacunza, Ezequiel, Montivero, Luciana et al.
DOI: 10.3892/or.2020.7648

FXYD5/Dysadherin, a Biomarker of Endometrial Cancer Myometrial Invasion and Aggressiveness: Its Relationship With TGF-beta1 and NF-kappaB Pathways.

PMID: 31867269
Journal: Frontiers in Oncology
Year: 2019
Reference: Front Oncol. 2019 Dec 6;9:1306. doi: 10.3389/fonc.2019.01306. eCollection 2019.
Impact factor: 4.137
Publication type: Paper in international publication
Authors: Besso, Maria Jose, Rosso, Marina, Lapyckyj, Lara, Moiola, Cristian Pablo, Matos, Maria Laura, Mercogliano, Maria Florencia, Schillaci, Roxana, Reventos, Jaume, Colas, Eva, Gil-Moreno, Antonio et al.
DOI: 10.3389/fonc.2019.01306

Detection of hyperfunctioning parathyroid tissue by (18)F-Fluorocholine PET/CT.

PMID: 29884517
Journal: Revista Espanola de Medicina Nuclear e Imagen Molecular
Year: 2019
Reference: Rev Esp Med Nucl Imagen Mol. 2019 Mar - Apr;38(2):118-120. doi: 10.1016/j.remn.2018.02.008. Epub 2018 Jun 5.
Impact factor: 0.928
Publication type: Paper in national publication
Authors: Villasboas-Rosciolesi, D, Garcia-Burillo, A, Gonzalez-Lopez, O, Castell-Conesa, J, Caubet-Busquet, E et al.
DOI: 10.1016/j.remn.2018.02.008

A giant superinfected uterine angioleiomyoma with distant septic metastases: an extremely rare presentation of a benign process and a systematic review of the literature.

PMID: 31435775
Journal: ARCHIVES OF GYNECOLOGY AND OBSTETRICS
Year: 2019
Reference: Arch Gynecol Obstet. 2019 Oct;300(4):841-847. doi: 10.1007/s00404-019-05267-w. Epub 2019 Aug 21.
Impact factor: 2.199
Publication type: Review in international publication
Authors: Sanchez-Iglesias, Jose-Luis, Capote, Sira, Cubo-Abert, Montserrat, Cabrera, Silvia, Illan-Hernandez, Lidia, Perez-Benavente, Maria-Assumpcio, Monreal-Clua, Sonia, Gil-Moreno, Antonio, Carbonell-Socias, Melchor et al.
DOI: 10.1007/s00404-019-05267-w

Nerve-sparing versus non-nerve-sparing radical hysterectomy: surgical and long-term oncological outcomes.

PMID: 31360307
Journal: Oncotarget
Year: 2019
Reference: Oncotarget. 2019 Jul 16;10(44):4598-4608. doi: 10.18632/oncotarget.27078. eCollection 2019 Jul 16.
Impact factor: 0
Publication type: Paper in international publication
Authors: Gil-Moreno, Antonio, Carbonell-Socias, Melchor, Bradbury, Melissa, Garcia, Angel, Verges, Ramona, Puig, Oriol Puig, Sanchez-Iglesias, Jose Luis, Cabrera-Diaz, Silvia, de la Torre, Javier, Gomez-Hidalgo, Natalia R et al.
DOI: 10.18632/oncotarget.27078

Laparoscopic Isthmocele Repair with Hysteroscopic Assistance.

PMID: 29032251
Journal: Journal of Minimally Invasive Gynecology
Year: 2018
Reference: J Minim Invasive Gynecol. 2018 May - Jun;25(4):576-577. doi: 10.1016/j.jmig.2017.10.005. Epub 2017 Oct 12.
Impact factor: 3.061
Publication type: Paper in international publication
Authors: Suarez Salvador, Elena, Haladjian, Cecilia, Bradbury, Melissa, Cubo-Abert, Montserrat, Manalich Barrachina, Laura, Vila Escude, Eva, Puig Puig, Oriol, Gil Moreno, Antonio et al.
DOI: 10.1016/j.jmig.2017.10.005

[Embolizing cardiac hibernoma and acute respiratory failure].

PMID: 30269781
Journal: Revista espanola de patologia : publicacion oficia
Year: 2018
Reference: Rev Esp Patol. 2018 Oct - Dec;51(4):267-270. doi: 10.1016/j.patol.2018.02.003. Epub 2018 Apr 5.
Impact factor: 0
Publication type: Paper in national publication
Authors: Montecino Romanini, Carolina, Reques Llanos, Armando, de Torres Ramirez, Ines, Rodriguez Morera, Jaime, Temprana Salvador, Jordi, Ramon Y Cajal, Santiago, Garcia Jimenez, Angel et al.
DOI: 10.1016/j.patol.2018.02.003

ALCAM shedding at the invasive front of the tumor is a marker of myometrial infiltration and promotes invasion in endometrioid endometrial cancer.

PMID: 29682175
Journal: Oncotarget
Year: 2018
Reference: Oncotarget. 2018 Mar 30;9(24):16648-16664. doi: 10.18632/oncotarget.24625. eCollection 2018 Mar 30.
Impact factor: 0
Publication type: Paper in international publication
Authors: Devis, Laura, Martinez-Garcia, Elena, Moiola, Cristian P, Quiles, Maria Teresa, Arbos, Maria Antonia, Stirbat, Tomita Vasilica, Brochard-Wyart, Francoise, Garcia, Angel, Alonso-Alconada, Lorena, Abal, Miguel et al.
DOI: 10.18632/oncotarget.24625

Nerve Sparing Technique during Laparoscopic Radical Hysterectomy: Critical Steps.

PMID: 29432901
Journal: Journal of Minimally Invasive Gynecology
Year: 2018
Reference: J Minim Invasive Gynecol. 2018 Nov - Dec;25(7):1144-1145. doi: 10.1016/j.jmig.2018.01.034. Epub 2018 Feb 9.
Impact factor: 3.061
Publication type: Paper in international publication
Authors: Diaz-Feijoo, Berta, Bradbury, Melisa, Perez-Benavente, Assumpcio, Franco-Camps, Silvia, Gil-Moreno, Antonio et al.
DOI: 10.1016/j.jmig.2018.01.034

Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.

PMID: 27997699
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2017
Reference: Int J Cancer. 2017 Apr 1;140(7):1551-1563. doi: 10.1002/ijc.30573. Epub 2017 Feb 2.
Impact factor: 5.531
Publication type: Paper in international publication
Authors: Garcia-Sanz, Pablo, Trivino, Juan Carlos, Mota, Alba, Perez Lopez, Maria, Colas, Eva, Rojo-Sebastian, Alejandro, Garcia, Angel, Gatius, Sonia, Ruiz, Maria, Prat, Jaime et al.
DOI: 10.1002/ijc.30573

Activated leukocyte cell adhesion molecule (ALCAM) is a marker of recurrence and promotes cell migration, invasion and metastasis in early stage endometrioid endometrial cancer.

PMID: 27873306
Journal: JOURNAL OF PATHOLOGY
Year: 2017
Reference: J Pathol. 2017 Mar;241(4):475-487. doi: 10.1002/path.4851. Epub 2017 Jan 23.
Impact factor: 7.381
Publication type: Letter or abstract
Authors: Devis, Laura, Moiola, Cristian P, Masia, Nuria, Martinez-Garcia, Elena, Santacana, Maria, Stirbat, Tomita Vasilica, Brochard-Wyart, Francoise, Garcia, Angel, Alameda, Francesc, Cabrera, Silvia et al.
DOI: 10.1002/path.4851

Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers.

PMID: 27586201
Journal: MODERN PATHOLOGY
Year: 2017
Reference: Mod Pathol. 2017 Jan;30(1):134-145. doi: 10.1038/modpathol.2016.143. Epub 2016 Sep 2.
Impact factor: 5.485
Publication type: Paper in international publication
Authors: Gonzalez-Tallada, Xavier, Diaz-Feijoo, Berta, Vidal, August, Ziober-Malinowska, Patrycja, Bobinski, Marcin, Lopez-Lopez, Rafael, Abal, Miguel, Reventos, Jaume, Matias-Guiu, Xavier, Moreno-Bueno, Gema et al.
DOI: 10.1038/modpathol.2016.143

Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.

PMID: 27903962
Journal: Oncotarget
Year: 2017
Reference: Oncotarget. 2017 Jan 17;8(3):4960-4976. doi: 10.18632/oncotarget.13634.
Impact factor: 5.008
Publication type: Paper in international publication
Authors: Celma, Ana, Bijnsdorp, Irene, Campos, Alex, Di Mauro, Primiano, Borros, Salvador, Reventos, Jaume, Doll, Andreas, Paciucci, Rosanna, Pegtel, Michiel, de Torres, Ines et al.
DOI: 10.18632/oncotarget.13634

Vulvar intraepithelial neoplasia: clinical presentation, management and outcomes in women infected with HIV.

PMID: 26959352
Journal: AIDS
Year: 2016
Reference: AIDS. 2016 Mar 27;30(6):859-68. doi: 10.1097/QAD.0000000000000984.
Impact factor: 4.407
Publication type: Paper in international publication
Authors: Bradbury, Melissa, Garcia-Jimenez, Angel, Franco-Camps, Silvia, Sanchez-Iglesias, Jose Luis, Diaz-Feijoo, Berta, Perez-Benavente, Assumpcio, Gil-Moreno, Antonio, Centeno-Mediavilla, Cristina, Cabrera, Silvia et al.
DOI: 10.1097/QAD.0000000000000984

Development of a sequential workflow based on LC-PRM for the verification of endometrial cancer protein biomarkers in uterine aspirate samples.

PMID: 27447978
Journal: Oncotarget
Year: 2016
Reference: Oncotarget. 2016 Aug 16;7(33):53102-53115. doi: 10.18632/oncotarget.10632.
Impact factor: 5.008
Publication type: Paper in international publication
Authors: Devis, Laura, Martinez-Garcia, Elena, Lesur, Antoine, van Oostrum, Jan, Matias-Guiu, Xavier, Gil-Moreno, Antonio, Reventos, Jaume, Colas, Eva, Domon, Bruno, Cabrera, Silvia et al.
DOI: 10.18632/oncotarget.10632

Exosome-like vesicles in uterine aspirates: a comparison of ultracentrifugation-based isolation protocols.

PMID: 27317346
Journal: Journal of Translational Medicine
Year: 2016
Reference: J Transl Med. 2016 Jun 18;14(1):180.
Impact factor: 3.694
Publication type: Paper in international publication
Authors: Campoy, Irene, Lanau, Lucia, Altadill, Tatiana, Sequeiros, Tamara, Cabrera, Silvia, Cubo-Abert, Montserrat, Perez-Benavente, Assumpcion, Garcia, Angel, Borros, Salvador, Santamaria, Anna et al.
DOI: 10.1186/s12967-016-0935-4

Enabling Metabolomics Based Biomarker Discovery Studies Using Molecular Phenotyping of Exosome-Like Vesicles.

PMID: 26974972
Journal: PLoS One
Year: 2016
Reference: PLoS One. 2016 Mar 14;11(3):e0151339. doi: 10.1371/journal.pone.0151339. eCollection 2016.
Impact factor: 3.057
Publication type: Paper in international publication
Authors: Altadill, Tatiana, Campoy, Irene, Lanau, Lucia, Gill, Kirandeep, Rigau, Marina, Gil-Moreno, Antonio, Reventos, Jaume, Byers, Stephen, Colas, Eva, Cheema, Amrita K et al.
DOI: 10.1371/journal.pone.0151339

Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.

PMID: 25219463
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2015
Reference: Int J Cancer. 2015 Apr 15;136(8):1863-73. doi: 10.1002/ijc.29213. Epub 2014 Sep 29.
Impact factor: 5.085
Publication type: Paper in international publication
Authors: Salvesen, Helga, Alonso-Alconada, Lorena, Santacana, Maria, Garcia-Sanz, Pablo, Muinelo-Romay, Laura, Colas, Eva, Mirantes, Cristina, Monge, Marta, Cueva, Juan, Oliva, Esther et al.
DOI: 10.1002/ijc.29213

Biological properties of extracellular vesicles and their physiological functions.

PMID: 25979354
Journal: Journal of Extracellular Vesicles
Year: 2015
Reference: J Extracell Vesicles. 2015 May 14;4:27066. doi: 10.3402/jev.v4.27066. eCollection 2015.
Impact factor:
Publication type: Letter or abstract
Authors: Heegaard, Niels H H, Yanez-Mo, Maria, Siljander, Pia R-M, Andreu, Zoraida, Zavec, Apolonija Bedina, Borras, Francesc E, Buzas, Edit I, Buzas, Krisztina, Casal, Enriqueta, Cappello, Francesco et al.
DOI:

Simultaneous treatment with statins and aspirin reduces the risk of prostate cancer detection and tumorigenic properties in prostate cancer cell lines.

PMID: 25649906
Journal: Biomed Research International
Year: 2015
Reference: Biomed Res Int. 2015;2015:762178. doi: 10.1155/2015/762178. Epub 2015 Jan 12.
Impact factor: 1.579
Publication type: Paper in international publication
Authors: de Torres, I, Doll, A, Morote, J, Reventos, J, Placer, J, Planas, J, Celma, A, Olivan, M, Rigau, M, Colas, E et al.
DOI: 10.1155/2015/762178

Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.

PMID: 25845829
Journal: PROSTATE
Year: 2015
Reference: Prostate. 2015 Jul;75(10):1102-13. doi: 10.1002/pros.22995. Epub 2015 Apr 1.
Impact factor: 3.565
Publication type: Paper in international publication
Authors: Sequeiros, Tamara, Bastaros, Juan M, Sanchez, Milagros, Rigau, Marina, Montes, Melania, Placer, Jose, Planas, Jaques, de Torres, Ines, Reventos, Jaume, Pegtel, D Michiel et al.
DOI: 10.1002/pros.22995

Giant urinary bladder stone: incidental finding in (99m)Tc-DTPA renography.

PMID: 24686214
Journal: CLIN NUCL MED
Year: 2014
Reference: Clin Nucl Med. 2014 Jul;39(7):667-8. doi: 10.1097/RLU.0000000000000432.
Impact factor: 2.857
Publication type: Letter or abstract
Authors: Garcia-Burillo, Amparo, Villasboas-Rosciolesi, Diego, Cardenas-Perilla, Rodrigo, Castell-Conesa, Joan et al.
DOI: 10.1097/RLU.0000000000000432

A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry.

PMID: 25282036
Journal: HUM PATHOL
Year: 2014
Reference: Hum Pathol. 2014 Dec;45(12):2394-403. doi: 10.1016/j.humpath.2014.06.031. Epub 2014 Aug 23.
Impact factor: 2.806
Publication type: Paper in international publication
Authors: Santacana, Maria, Maiques, Oscar, Gatius, Sonia, Abo, Ana Isabel, Lopez-Garcia, Maria Angeles, Mota, Alba, Reventos, Jaume, Moreno-Bueno, Gema, Palacios, Jose, Bartosch, Carla et al.
DOI: 10.1016/j.humpath.2014.06.031

Role of p53 pathway alterations in uterine carcinosarcomas (malignant mixed Mullerian tumors).

PMID: 25033979
Journal: ONCOLOGY-BASEL
Year: 2014
Reference: Oncology. 2014;87(4):193-204. doi: 10.1159/000363574. Epub 2014 Jul 11.
Impact factor: 2.613
Publication type: Review in national publication
Authors: Semczuk, Andrzej, Ignatov, Atanas, Obrzut, Bogdan, Reventos, Jaume, Rechberger, Tomasz et al.
DOI: 10.1159/000363574

Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.

PMID: 25261936
Journal: MOL CANCER
Year: 2014
Reference: Mol Cancer. 2014 Sep 27;13:223. doi: 10.1186/1476-4598-13-223.
Impact factor: 5.397
Publication type: Paper in international publication
Authors: Cueva, Juan, Vieito, Maria, Ortega, Eugenia, Mariscal, Javier, Colas, Eva, Castellvi, Josep, Cusido, Maite, Dolcet, Xavier, Nijman, Hans W, Bosse, Tjalling et al.
DOI: 10.1186/1476-4598-13-223

Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.

PMID: 24371818
Journal: BioMed research international [electronic resource]
Year: 2013
Reference: Biomed Res Int. 2013;2013:283635. doi: 10.1155/2013/283635. Epub 2013 Nov 25.
Impact factor:
Publication type: Letter or abstract
Authors: Doll, Andreas, Reventos, Jaume, Morote, Juan, de Torres, Ines, Sequeiros, Tamara, Garcia, Marta, Montes, Melania, Olivan, Mireia, Rigau, Marina, Colas, Eva et al.
DOI: 10.1155/2013/283635

The present and future of prostate cancer urine biomarkers.

PMID: 23774836
Journal: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Year: 2013
Reference: Int J Mol Sci. 2013 Jun 17;14(6):12620-49. doi: 10.3390/ijms140612620.
Impact factor: 2.464
Publication type: Paper in international publication
Authors: Rigau, Marina, Olivan, Mireia, Garcia, Marta, Sequeiros, Tamara, Montes, Melania, Colas, Eva, Llaurado, Marta, Planas, Jacques, Torres, Ines de, Morote, Juan et al.
DOI: 10.3390/ijms140612620

[Molecular biology of bone metastases].

PMID: 23793764
Journal: Archivos españoles de urología
Year: 2013
Reference: Arch Esp Urol. 2013 Jun;66(5):463-74.
Impact factor:
Publication type: Letter or abstract
Authors: Reventos, Jaume, Doll, Andreas, Garcia, Marta, Rigau, Marina, Olivan, Mireia, Montes, Melania, Sequeiros, Tamara, Llaurado, Marta, Colas, Eva, Morote, Juan et al.
DOI:

Molecular diagnosis of endometrial cancer from uterine aspirates.

PMID: 23649867
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2013
Reference: Int J Cancer. 2013 Nov 15;133(10):2383-91. doi: 10.1002/ijc.28243. Epub 2013 Jun 21.
Impact factor: 6.198
Publication type: Paper in international publication
Authors: Xercavins, Jordi, Perez-Sanchez, Cristina, Colas, Eva, Cabrera, Silvia, Falcon, Orlando, Sanchez-Del-Rio, Angel, Garcia, Enrique, Fernandez-de-Castillo, Luis, Muruzabal, Juan Carlos, Alvarez, Elena et al.
DOI: 10.1002/ijc.28243

Notch-mediated induction of N-cadherin and alpha9-integrin confers higher invasive phenotype on rhabdomyosarcoma cells.

PMID: 22976797
Journal: BRITISH JOURNAL OF CANCER
Year: 2012
Reference: Br J Cancer. 2012 Oct 9;107(8):1374-83. doi: 10.1038/bjc.2012.411. Epub 2012 Sep 13.
Impact factor: 5.042
Publication type: Paper in international publication
Authors: Sanchez de Toledo, J, Roma, J, Gallego, S, Toran, N, Reventos, J, Almazan-Moga, A, Masia, A, Velasco, P et al.
DOI: 10.1038/bjc.2012.411

The EMT signaling pathways in endometrial carcinoma.

PMID: 22911547
Journal: Clinical & Translational Oncology
Year: 2012
Reference: Clin Transl Oncol. 2012 Oct;14(10):715-20. doi: 10.1007/s12094-012-0866-3. Epub 2012 Aug 22.
Impact factor: 1.327
Publication type: Review in international publication
Authors: Garcia, Angel, Ramon Y Cajal, Santiago, Moreno-Bueno, Gema, Dolcet, Xavier, Alameda, Francesc, Palacios, Jose, Prat, Jaime, Doll, Andreas, Matias-Guiu, Xavier, Abal, Miguel et al.
DOI: 10.1007/s12094-012-0866-3

Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease.

PMID: 22037169
Journal: MOLECULAR AND CELLULAR ENDOCRINOLOGY
Year: 2012
Reference: Mol Cell Endocrinol. 2012 Jul 25;358(2):244-55. Epub 2011 Oct 20.
Impact factor: 4.192
Publication type: Review in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1016/j.mce.2011.10.003

Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FoxM1 over-expression in ovarian cancer.

PMID: 22589409
Journal: MOLECULAR CANCER RESEARCH
Year: 2012
Reference: Mol Cancer Res. 2012 Jul;10(7):914-24. doi: 10.1158/1541-7786.MCR-11-0449. Epub 2012 May 15.
Impact factor: 4.288
Publication type: Paper in international publication
Authors: , , , , , , et al.
DOI: 10.1158/1541-7786.MCR-11-0449

Apoptosis-like cell death induction and aberrant fibroblast properties in human incisional hernia fascia.

PMID: 21641387
Journal: AMERICAN JOURNAL OF PATHOLOGY
Year: 2011
Reference: Am J Pathol. 2011 Jun;178(6):2641-53.
Impact factor: 5.224
Publication type: Paper in international publication
Authors: Guillem-Marti, Jordi, Lopez-Cano, Manuel, Huguet, Pere, Ramon-Y-Cajal, Santiago, Reventos, Jaume, Armengol, Manel, Arbos, Maria A, Quiles, Maria T, Diaz, Ramon et al.
DOI: 10.1016/j.ajpath.2011.02.044

High risk endometrial carcinoma profiling identifies TGF-{beta}1 as a key factor in the initiation of tumor invasion.

PMID: 21613448
Journal: MOLECULAR CANCER THERAPEUTICS
Year: 2011
Reference: Mol Cancer Ther. 2011 Aug;10(8):1357-66. Epub 2011 May 25.
Impact factor: 5.225
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1158/1535-7163.MCT-10-1019

A Three-Gene panel on urine increases PSA specificity in the detection of prostate cancer.

PMID: 21520154
Journal: PROSTATE
Year: 2011
Reference: Prostate. 2011 Dec;71(16):1736-45. doi: 10.1002/pros.21390. Epub 2011 Apr 25.
Impact factor: 3.377
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1002/pros.21390

Matrix metalloproteinase-2 and matrix metalloproteinase-9 codistribute with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma.

PMID: 20970160
Journal: HUMAN PATHOLOGY
Year: 2011
Reference: Hum Pathol. 2011 Jan;42(1):57-67. Epub 2010 Oct 20.
Impact factor: 2.998
Publication type: Paper in international publication
Authors: , , , , , , et al.
DOI: 10.1016/j.humpath.2010.01.025

Human SHBG mRNA Translation Is Modulated by Alternative 5'-Non-Coding Exons 1A and 1B.

PMID: 21079794
Journal: PLoS One
Year: 2010
Reference: PLoS One. 2010 Nov 4;5(11):e13844.
Impact factor: 4.351
Publication type: Paper in international publication
Authors: , , , , , , et al.
DOI: 10.1371/journal.pone.0013844

Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia.

PMID: 20607245
Journal: WORLD JOURNAL OF UROLOGY
Year: 2010
Reference: World J Urol. 2010 Dec;28(6):677-80. Epub 2010 Jul 7.
Impact factor: 2.629
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1007/s00345-010-0580-0

PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine.

PMID: 20672322
Journal: PROSTATE
Year: 2010
Reference: Prostate. 2010 Dec 1;70(16):1760-7.
Impact factor: 3.081
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1002/pros.21211

A transcriptional signature associated with the onset of benign prostate hyperplasia in a canine model.

PMID: 20687213
Journal: PROSTATE
Year: 2010
Reference: Prostate. 2010 Sep 15;70(13):1402-12.
Impact factor: 3.081
Publication type: Paper in international publication
Authors: Gallardo-Arrieta, F, Doll, A, Rigau, M, Mogas, T, Juanpere, N, Garcia, F, Morote, J, Nunez, F, Abal, M, Lloreta, J et al.
DOI: 10.1002/pros.21175

MMPs/TIMPs and inflammatory signalling deregulation in human incisional hernia tissues.

PMID: 19397782
Journal: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
Year: 2009
Reference: J Cell Mol Med. 2009 Nov-Dec;13(11-12):4432-43.
Impact factor: 5.114
Publication type: Paper in international publication
Authors: , , , , , , , , , et al.
DOI: 10.1111/j.1582-4934.2008.00637.x

Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate.

PMID: 19534810
Journal: BMC MOLECULAR BIOLOGY
Year: 2009
Reference: BMC Mol Biol. 2009 Jun 17;10:59.
Impact factor: 2.81
Publication type: Paper in international publication
Authors: Munell, Francina, Morote, Joan, Pinos, Tomas, Barbosa-Desongles, Anna, Hurtado, Antoni, Santamaria-Martinez, Albert, de Torres, Ines, Reventos, Jaume et al.
DOI: 10.1186/1471-2199-10-59

An orthotopic endometrial cancer mouse model demonstrates a role for RUNX1 in distant metastasis.

PMID: 19384951
Journal: INTERNATIONAL JOURNAL OF CANCER
Year: 2009
Reference: Int J Cancer. 2009 Jul 15;125(2):257-63.
Impact factor: 4.734
Publication type: Paper in international publication
Authors: Abal, Miguel, Doll, Andreas, Gonzalez, Marta, Colas, Eva, Monge, Marta, Xercavins, Jordi, Capella, Gabriel, Diaz, Berta, Gil-Moreno, Antonio, Alameda, Francesc et al.
DOI: 10.1002/ijc.24330

Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy.

PMID: 19007366
Journal: BJU INTERNATIONAL
Year: 2009
Reference: BJU Int. 2009 Feb;103(3):332-5; discussion 335.
Impact factor: 2.704
Publication type: Paper in international publication
Authors: Morote, Juan, Planas, Jacques, Salvador, Carlos, Raventos, Carles X, Catalan, Roberto, Reventos, Jaume et al.
DOI: 10.1111/j.1464-410X.2008.08062.x

Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells.

PMID: 18607069
Journal: CELLULAR ONCOLOGY
Year: 2008
Reference: Cell Oncol. 2008;30(4):349-65.
Impact factor: 4.17
Publication type: Paper in international publication
Authors: de Torres, Ines, Bellmunt, Joaquim, Reventos, Jaume, Munell, Francina, Morote, Joan, Santamaria-Martinez, Albert, Barquinero, Jordi, Hurtado, Antoni, Pinos, Tomas, Barbosa-Desongles, Anna et al.
DOI:

Thesis

Shaping endometrial cancer diagnosis via the identification of protein biomarkers in gynecological fluids

PhD student: Eva Coll De la Rubia
Director/s: Antonio Gil Moreno, Eva Colas Ortega, Silvia Cabrera Diaz
University: Universitat Autònoma de Barcelona
Year: 2022

Utilidad diagnóstica del test intraoperatorio del virus del papiloma humano como marcador precoz de curación o recidiva en mujeres con neoplasia intraepitelial cervical de alto grado (HSIL/CIN2-3)

PhD student: Jordi Rabasa Antonijuan
Director/s: Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2020

Impacto del uso de la sutura de absorción retardada en la incidencia de dehiscencia de la cúpula vaginal, después de la histerectomía laparoscópica y robótica

PhD student: Elena Suarez Salvador
Director/s: Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2020

Estudi de cohorts prospectiu del tractament quirúrgic de la incontinència urinària de esforç femenina amb bandes suburetrals transobturadores

PhD student: Jose Luis Poza Barrasus
Director/s: Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2020

Targeting mitosis in ovarian cancer: The study of Bora as a future therapeutic avenue

PhD student: Alfonso Parrilla Ocon
Director/s: Anna Santamaria Margalef
University: Universitat Autònoma de Barcelona
Year: 2019

EV-associated miRNAs as a new source of biomarkers in endometrial, colorectal and lung cancers

PhD student: Berta Román Canal
Director/s: Eva Colas Ortega
University: Universitat Autònoma de Barcelona
Year: 2019

Metabolomic study for the identification of diagnostic markers and the characterization of the dissemination process of endometrial cancer

PhD student: Tatiana Altadill Vallespi
Director/s: Eva Colas Ortega, Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2018

Molecular alteracions in eutopic endometrium of women with endometriosis and implications in its diagnostic

PhD student: Júlia Vallvé Juanico
Director/s: Xavier Santamaria Costa, Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2018

The role of activated leukocyte cell adhesion molecule (ALCAM) in endometrial cancer progression and dissemination

PhD student: Laura Devis Jauregui
Director/s: Jaume Reventós Puigjaner, Eva Colas Ortega, Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2017

Nuevas moléculas asociadas al cáncer de ovario para la mejora de su diagnóstico y tratamiento

PhD student: Lucia Lanau Angulo
Director/s: Anna Santamaria Margalef, Jaume Reventós Puigjaner, Marina Rigau Resina
University: Universitat Autònoma de Barcelona
Year: 2017

Protein signatures in uterine aspirates to improve diagnosis of endometrial cancer. The CEMARK project

PhD student: Elena Martínez García
Director/s: Eva Colas Ortega, Antonio Gil Moreno, Jaume Reventós Puigjaner
University: Universitat Autònoma de Barcelona
Year: 2017

Micro-RNAs in ovarian cancer as tools for diagnosis and therapy

PhD student: Blanca Majem Cavaller
Director/s: Anna Santamaria Margalef
University: Universitat Autònoma de Barcelona
Year: 2017

Estudio comparativo entre cirugía primaria y cirurgia de intervalo en el estadio IIIC del cáncer de ovario

PhD student: José Luis Sánchez Iglesias
Director/s: Antonio Gil Moreno
University: Universitat Autònoma de Barcelona
Year: 2014

Identification of New Urine Biomarkers for the Detection of Prostate Cancer

PhD student: Marina Rigau Resina
Director/s: Jaume Reventós Puigjaner, Andreas He Doll , Joan Morote Robles
University: Universitat Autònoma de Barcelona
Year: 2011

Endometrial carcinoma: improving diagnosis, deconstructing carcinoma invasion and pursuing new therapeutic strategies

PhD student: Eva Colas Ortega
Director/s: Jaume Reventós Puigjaner
University: Universitat Autònoma de Barcelona
Year: 2011

Estudio prospectivo para la validacion de la tecnica del ganclio centinela en cáncer de cervix uterino inicial

PhD student: Berta Diaz Feijoo
Director/s:
University: Universitat Autònoma de Barcelona
Year: 2007

Blog

News

La Recuperació Intensificada en Cirurgia aconsegueix que el procés perioperatori de les pacients de ginecologia oncològica millori, escurçant l'estada hospitalària, els reingressos, les complicacions postoperatòries i el confort de les pacients.

The AECC Research Grants for 2021 will drive the research headed by Dr Fernanda da Silva and Dr Eva Colás.

In this IV edition, 4,800 euros have been raised, which will go to the Biomedical Research in Gynecology group at Vall d'Hebron Research.

Job offers

Postdoctoral position-Biomedical Research in Gynecology
Start date:
13/12/2021
End date:
25/01/2022
Document: Download
Predoctoral position - Group of Biomedical Research in Gynecology..
Start date:
19/10/2021
End date:
02/11/2021
Document: Download
Fellow in Gynecology Oncology
Start date:
22/09/2021
End date:
06/10/2021
Document: Download